Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194117 | 0.95 | CPN1 (0.38) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL28103000 | 0.90 | CPN1 (0.31) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL4436455 | 0.83 | GAA (0.32) | SMN1; SMN2GAA | |
| SCHEMBL1919959 | 0.83 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL20594008 | 0.83 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL27371104 | 0.83 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL20594016 | 0.83 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL27678408 | 0.83 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL4272078 | 0.82 | CPN1 (0.47) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL6216734 | 0.81 | CPN1 (0.42) | CPN1CPB2SLC6A1SLC6A11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104470934-B | Kinases inhibitor | 爱仕达生物技术有限责任公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-106795152-A | Protein kinase inhibitors | 安斯达尔生物技术有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-104470934-A | Protein kinase inhibitors | ASTAR BIOTECH LLC | 2015-03-25 | — | — | CN | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20070249676-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-10-25 | — | — | US | disclosed |
| US-7253193-B2 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-08-07 | — | — | US | disclosed |
| EP-1507760-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2007-08-01 | — | — | EP | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215588-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2005-09-29 | — | — | US | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1507760-A1 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097601-A1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| CN-1044365-C | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis | SANKYO CO (JP) | 1999-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249676-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | CPN1 187/4885CPB2 553/4885SLC6A1 2928/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | CPN1 3694/4885CPB2 4102/4885SLC6A1 3282/4885 |
| US-20050215588-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | CPN1 187/4885CPB2 553/4885SLC6A1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.